(Q33762036)

29 July 2017

Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction (English)

1 reference

29 July 2017

Jollis JG

1

1 reference

29 July 2017

Simpson RJ Jr

2

1 reference

29 July 2017

Cascio WE

3

1 reference

29 July 2017

Chowdhury MK

4

1 reference

29 July 2017

Crouse JR 3rd

5

1 reference

29 July 2017

Smith SC Jr

6

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 November 1999

1 reference

29 July 2017

American Heart Journal

1 reference

29 July 2017

138

1 reference

29 July 2017

5 Pt 1

1 reference

29 July 2017

S376-80

1 reference

A study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970038-4

Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970038-4

Cardiovascular effects of oral hypoglycaemic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970038-4

Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970038-4

Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970038-4

Using admission characteristics to predict short-term mortality from myocardial infarction in elderly patients. Results from the Cooperative Cardiovascular Project.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970038-4

Therapy of type 2 diabetes, cardiovascular death, and the UGDP

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970038-4

A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970038-4

Controversy Over Study of Diabetes Drugs Continues for Nearly a Decade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970038-4

The crux of the UGDP. Spurious results and biologically inappropriate data analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970038-4

Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970038-4

Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970038-4

7 January 2021

Oral hypoglycemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970038-4

Vascular complications and long-term administration of oral hypoglycemic agents in patients with diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970038-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-8703(99)70038-4

1 reference

29 July 2017

1 reference